Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn MoreAdenocarcinoma is a relatively rare malignancy in the urinary bladder, which can originate primarily within the bladder or secondarily from various other organs. Alfa Cytology, as a leading global authority in bladder cancer research, leverages our extensive expertise and advanced platform to provide unparalleled research services for adenocarcinoma.
Grossly, bladder adenocarcinoma typically originates from the trigone and posterior wall but can manifest in any region of the bladder. It commonly presents as a solitary lesion, in contrast to urothelial carcinoma which tends to be multifocal. Macroscopically, the tumor may exhibit papillary, sessile, solid, or ulcerating characteristics. The cut surface often displays a gelatinous appearance due to abundant mucin production.
Histologically, bladder adenocarcinoma exhibits various growth patterns.
Fig.1 Enteric-type bladder adenocarcinoma shows intestinal-type glands with columnar cells and marked cytologic atypia. (Dadhania, V., et al., 2015)
Fig.2 Mucinous-type bladder adenocarcinoma produces abundant extracellular mucin, forming a pool of mucin with floating tumor cells. (Dadhania, V., et al., 2015)
Fig.3 Signet ring cell-type bladder adenocarcinoma is characterized by large intracellular mucin vacuoles that displace nuclei to the periphery. (Dadhania, V., et al., 2015)
The following is some therapies information regarding adenocarcinoma of the bladder cancer.
Therapeutics | Mechanism of Action | Phase | Observed Effects |
---|---|---|---|
Nivolumab | PD-1 Inhibitor | Phase II | Increased Overall Survival Rates |
Atezolizumab | PD-L1 Inhibitor | Phase III | Improved Response Rates in Metastatic Cases |
Pembrolizumab | PD-1 Inhibitor | Phase II | Effective in Treating High-Risk, BCG-Unresponsive Patients |
Enfortumab Vedotin | ADC Targeting Nectin-4 | Phase III | Significant Tumor Reduction and Improved Patient Outcomes |
Erdafitinib | FGFR Inhibitor | Phase II | Efficacy in Patients with FGFR Genetic Alterations |
Alfa Cytology offers a comprehensive range of research services tailored to address the complex pathophysiology of adenocarcinoma and facilitate the development of effective diagnostic and therapeutic strategies.
Ongoing research and advancements in the understanding of adenocarcinoma biology continue to drive the development of innovative therapeutic approaches. At Alfa Cytology, we are dedicated to providing comprehensive and state-of-the-art solutions for adenocarcinoma therapy development. For further information regarding our extensive services, please do not hesitate to contact us.
Reference
Alfa Cytology is dedicated to drug development and preclinical services for bladder cancer.